Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16263337 | 0.78 | SRD5A1 (0.36) | HTTTDP1SRD5A1SRD5A2ALDH1A1 | |
| SCHEMBL20192211 | 0.76 | HTT (0.43) | HTTTDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL16263343 | 0.76 | HTT (0.43) | HTTTDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL15079018 | 0.72 | HTT (0.38) | HTTTDP1ALDH1A1POLBRAB9A | |
| SCHEMBL16263338 | 0.71 | TDP1 (0.37) | HTTTDP1SRD5A1SRD5A2ALDH1A1 | |
| SCHEMBL16263348 | 0.67 | MEN1 (0.39) | HTTTDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL16263339 | 0.66 | BACE1 (0.41) | RAB9A | |
| SCHEMBL18104012 | 0.65 | KMT2A (0.36) | ALDH1A1MEN1POLBKMT2ARAB9A | |
| SCHEMBL15079061 | 0.64 | CYP46A1 (0.36) | HTTMEN1POLBKMT2ARAB9A | |
| SCHEMBL16263344 | 0.64 | CYP46A1 (0.36) | HTTMEN1POLBKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | GFPT1, NUDT1, INF2 | HTT 1333/4885TDP1 2260/4885SRD5A1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.